Dutch biotech firm, VectorY, has raised $138m to advance its antibody technology in the treatment of neurodegenerative diseases, particularly ALS. By targeting the misfolded protein TDP-43 with antibodies, VectorY’s drug therapy could potentially tackle an aggressive form of ALS that has previously proved difficult to treat. The funding will be used to push the lead programme, VTX-002, into clinical trials which are hoped to begin in early 2025.
Researchers Replicated DeepSeek’s R1-Zero Model for Just $30
Researchers have replicated DeepSeek’s R1-Zero model as TinyZero for $30, focusing on countdown and multiplication tasks using reinforcement learning on a 3-billion-parameter language model. This
